Price Alert

Delcath Systems Inc. (DCTH)

NASDAQ: DCTH · Real-Time Price · USD

11.10

0.45 (4.23%)

At close: Oct 03, 2025, 3:59 PM

11.30

1.80%

After-hours: Oct 03, 2025, 07:45 PM EDT

4.23% (1D)

Bid	8.04
Market Cap	388.29M
Revenue (ttm)	68.6M
Net Income (ttm)	2.23M
EPS (ttm)	0.09
PE Ratio (ttm)	123.33
Forward PE	19.02
Analyst	Strong Buy
Dividends	n/a

Ask	13.81
Volume	606,886
Avg. Volume (20D)	714,865
Open	10.74
Previous Close	10.65
Day's Range	10.70 - 11.21
52-Week Range	8.08 - 18.23
Beta	0.84
Ex-Dividend Date	n/a

About DCTH

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DCTH

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DCTH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Delcath Systems Inc. is scheduled to release its earnings on Nov 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+1.14%

Delcath Systems shares are trading higher after th... Unlock content with Pro Subscription

4 months ago

-6.32%

DCTH stock has given up its prior gain. Delcath Systems shares were trading higher after the company issued FY25 guidance and provided business updates.

News

1 week ago · businesswire.com

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the accept...

1 month ago · businesswire.com

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of t...

1 month ago · businesswire.com

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

2 months ago · seekingalpha.com

Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript

Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Ger...

2 months ago · fool.com

Delcath (DCTH) Q2 Revenue Jumps 210%

1 month ago · zacks.com

Delcath Systems, Inc. (DCTH) Surpasses Q2 Earnings and Revenue Estimates

Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.48 per share a year ago.

1 month ago · businesswire.com

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancer...

2 months ago · businesswire.com

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced tha...